Genomic Health launches Oncotype DX colon cancer test
This article was originally published in Clinica
Genomic Health has launched worldwide its Oncotype DX test to assess the recurrence risk of colon cancer. The diagnostic, which analyses 12 genes, is intended for patients with stage II disease following surgery. These patients often receive chemotherapy, but only around 2-4% benefit. Identifying who is likely to experience a recurrence could help spare patients from treatment they do not need. Genomic Health (Redwood City, California) plans to present data from two studies of the test at the ASCO Gastrointestinal Symposium this month, showing its efficacy in stage II patients, and suggesting that it might also be useful in stage III disease. The company also markets an Oncotype DX test to predict the likelihood of recurrence of breast cancer.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.